MicroRNA-21 is a potential link between non-alcoholic fatty liver disease and hepatocellular carcinoma via modulation of the HBP1-p53-Srebp1c pathway
View abstract on PubMed
Summary
This summary is machine-generated.MicroRNA-21 promotes non-alcoholic fatty liver disease and liver cancer by affecting the Hbp1-p53-Srebp1c pathway. Inhibiting microRNA-21 may offer a therapeutic strategy for these conditions.
Area Of Science
- Hepatology
- Molecular Biology
- Oncology
Background
- Non-alcoholic fatty liver disease (NAFLD) is a significant risk factor for hepatocellular carcinoma (HCC).
- The precise mechanistic links between NAFLD and HCC remain largely undefined.
- Understanding these pathways is crucial for developing effective therapeutic strategies.
Purpose Of The Study
- To investigate the role of microRNA-21 (miR-21) in the development of NAFLD.
- To explore the potential involvement of miR-21 in the pathogenesis of HCC.
- To elucidate the molecular mechanisms underlying miR-21's function in liver disease and cancer.
Main Methods
- Utilized a high-fat diet (HFD) mouse model with microRNA-21-anti-sense oligonucleotide (ASO) treatment.
- Employed human hepatoma HepG2 cells treated with oleate to study lipogenesis.
- Assessed miR-21's role in carcinogenesis using soft-agar assays, cell cycle analysis, and xenograft tumor models.
Main Results
- Increased miR-21 expression was observed in HFD-fed mice and fatty acid-treated HepG2 cells.
- Knockdown of miR-21 reduced hepatic lipid accumulation and inhibited tumor growth in vivo.
- Identified Hbp1 as a novel miR-21 target, which activates p53, a suppressor of lipogenesis and cell proliferation.
Conclusions
- MicroRNA-21 promotes hepatic lipid accumulation and cancer progression via the Hbp1-p53-Srebp1c pathway.
- This study reveals a novel mechanism linking NAFLD and HCC pathogenesis.
- MicroRNA-21-ASO emerges as a potential therapeutic agent for both NAFLD and HCC.